Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer | Semantic Scholar Skip to search formSkip to main content> Semantic Scholar's Logo Search Sign InCreate Free Account You are currently offline. Some features of the site may not work correctly. DOI:10.4103/sajc.sajc_122_18 Corpus ID: 14015493Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer @article{Gupta2018PracticalCR, title={Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer}, author={S. Gupta and M. Singh and A. Vora and G. Babu and M. Walia and V. Nautial and R. Saha and B. Smruti and J. Sharma and R. Koul and P. Parikh and S. Aggarwal}, journal={South Asian Journal of Cancer}, year={2018}, volume={7}, pages={142 - 145} } S. Gupta, M. Singh, +9 authors S. Aggarwal Published 2018 Medicine South Asian Journal of Cancer Optimization of adjuvant systemic therapy in women with early-stage hormone receptor-positive breast cancer includes the consideration of chemotherapy and duration of hormone therapy. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency… Expand View on Wolters Kluwer ncbi.nlm.nih.gov Save to Library Create Alert Cite Launch Research Feed Share This Paper 1 Citations View All Tables and Topics from this paper table 2 table 3 table 4 Mammary Neoplasms Tamoxifen Hormone Therapy Pharmaceutical Adjuvants systemic therapy American Society of Clinical Oncology Conflict (Psychology) Aromatase Inhibitors Scientific Publication One Citation Citation Type Citation Type All Types Cites Results Cites Methods Cites Background Has PDF Publication Type Author More Filters More Filters Filters Sort by Relevance Sort by Most Influenced Papers Sort by Citation Count Sort by Recency Breast Cancer Demographics, Types and Management Pathways: Can Western Algorithms be Optimally used in Eastern Countries? S. Chakraborty, T. Wadasadawala, R. Ahmed, C. Coles, S. Chatterjee Medicine Clinical oncology (Royal College of Radiologists (Great Britain)) 2019 2 Save Alert Research Feed References SHOWING 1-10 OF 49 REFERENCES SORT BYRelevance Most Influenced Papers Recency Duration of adjuvant tamoxifen therapy. J. Bryant, B. Fisher, J. Dignam Medicine Journal of the National Cancer Institute. Monographs 2001 60 PDF Save Alert Research Feed American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. E. Winer, C. Hudis, +19 authors M. Somerfield Medicine Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 992 Save Alert Research Feed Adherence to Endocrine Therapy for Breast Cancer R. Chlebowski, Michelle L Geller Medicine Oncology 2006 179 Save Alert Research Feed Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. F. Boccardo, A. Rubagotti, +17 authors P. Sismondi Medicine Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 439 PDF Save Alert Research Feed Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. B. Fisher, J. Dignam, +18 authors H. L. Lickley Medicine Journal of the National Cancer Institute 1996 856 PDF Save Alert Research Feed Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. V. Ziller, M. Kalder, +4 authors P. Hadji Medicine Annals of oncology : official journal of the European Society for Medical Oncology 2009 235 Save Alert Research Feed Use of tamoxifen for breast cancer: twenty-eight years later. I. Jaiyesimi, A. Buzdar, D. Decker, G. Hortobagyi Medicine Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995 387 Save Alert Research Feed Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial R. Jakesz, W. Jonat, +10 authors M. Kaufmann Medicine The Lancet 2005 838 Save Alert Research Feed Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. Medicine Journal of the National Cancer Institute 1996 38 Save Alert Research Feed Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group Medicine The Lancet 2005 3,789 PDF Save Alert Research Feed ... 1 2 3 4 5 ... Related Papers Abstract Tables and Topics 1 Citations 49 References Related Papers Stay Connected With Semantic Scholar Sign Up About Semantic Scholar Semantic Scholar is a free, AI-powered research tool for scientific literature, based at the Allen Institute for AI. Learn More → Resources DatasetsSupp.aiAPIOpen Corpus Organization About UsResearchPublishing PartnersData Partners   FAQContact Proudly built by AI2 with the help of our Collaborators Terms of Service•Privacy Policy The Allen Institute for AI By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License ACCEPT & CONTINUE